Ignite Creation Date:
2025-12-24 @ 9:36 PM
Ignite Modification Date:
2025-12-25 @ 7:19 PM
Study NCT ID:
NCT05576532
Status:
UNKNOWN
Last Update Posted:
2023-06-28
First Post:
2022-10-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-01-10
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-10-10
Completion Date Type:
ESTIMATED
First Submit Date:
2022-10-09
First Submit QC Date:
None
Study First Post Date:
2022-10-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-06-27
Last Update Post Date:
2023-06-28
Last Update Post Date Type:
ACTUAL